Search results
Keeler Thomas Management LLC Lowers Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 6 days agoKeeler Thomas Management LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 15.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC ...
Harbor Advisory Corp MA Decreases Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 10 hours agoHarbor Advisory Corp MA lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities ...
Barrington Research Reaffirms Outperform Rating for Option Care Health (NASDAQ:OPCH)
ETF DAILY NEWS· 6 days agoBarrington Research restated their outperform rating on shares of Option Care Health (NASDAQ:OPCH –...
VTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc....
The Sun Chronicle· 5 days agoNEW YORK, April 29, 2024 /PRNewswire/ --
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort...
Benzinga· 21 hours agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
Johnson & Johnson (NYSE:JNJ) Stock Holdings Decreased by Mitchell Mcleod Pugh & Williams Inc.
ETF DAILY NEWS· 10 hours agoMitchell Mcleod Pugh & Williams Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 28,869 ...
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 2 days agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 4 days agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number of other analysts ...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 3 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports. Barclays‘s ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 4 days agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie traded as low as $158.56 and last ...